<DOC>
	<DOCNO>NCT00182637</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well bortezomib work treat patient relapsed refractory cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Relapsed Refractory Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( complete response partial response ) duration response patient relapse refractory cutaneous T-cell lymphoma treat bortezomib . - Determine safety tolerability drug patient . OUTLINE : This open-label study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month least every 3 month 2 year disease progression . PROJECTED ACCRUAL : A total 15-25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm cutaneous Tcell lymphoma , include mycosis fungoides/Sézary syndrome Stage IBIV disease Relapsed refractory disease OR intolerant ≥ 1 prior systemic therapy Measurable disease radiological image clinical finding Age Over 18 Performance status Karnofsky 70100 % Hematopoietic WBC &gt; 2,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 75,000/mm^3 Hemoglobin &gt; 8.0 g/dL Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 3 time ULN Renal Creatinine &lt; 1.5 time ULN Creatinine clearance ≥ 30 mL/min Negative pregnancy test Fertile patient must use effective contraception More 3 month since prior highdose chemotherapy More 30 day since prior concurrent investigational drug history myelodysplastic syndrome evidence CNS disease pregnant nursing peripheral neuropathy ≥ grade 2 hypersensitivity bortezomib , boron , mannitol serious medical condition psychiatric illness would preclude study participation concurrent immunotherapy concurrent chemotherapy concurrent steroid dose &gt; 10 mg/day prednisone equivalent concurrent radiotherapy concurrent surgery malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>